Insight Molecular Diagnostics Inc.
IMDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001642380
No open-market purchases or sales by Insight Molecular Diagnostics Inc. insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $108.9M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Insight Molecular Diagnostics Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- −2 vs. Q1 2024
- Shares held
- 7.14M
- +2.77M (+63.5%) vs. Q1 2024
- Total value
- $21.1M
- +$8.27M (+64.6%) vs. Q1 2024
- New holders
- 3
- 8 more added
- Sold out
- 5
- 6 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IMDX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 40 | $108.9M |
| Q1 2026 | 41 | $62.1M |
| Q4 2025 | 35 | $124.9M |
| Q3 2025 | 27 | $54.1M |
| Q2 2025 | 30 | $48.9M |
| Q1 2025 | 30 | $49.2M |
| Q4 2024 | 27 | $20.0M |
| Q3 2024 | 21 | $20.4M |
| Q2 2024 | 23 | $21.1M |
| Q1 2024 | 25 | $13.5M |
| Q4 2023 | 26 | $11.4M |
| Q3 2023 | 30 | $14.3M |
| Q2 2023 | 47 | $21.1M |
| Q1 2023 | 52 | $19.7M |
| Q4 2022 | 59 | $19.6M |
| Q3 2022 | 65 | $48.4M |
| Q2 2022 | 76 | $61.9M |
| Q1 2022 | 86 | $81.2M |
| Q4 2021 | 89 | $120.3M |
| Q3 2021 | 95 | $201.9M |
| Q2 2021 | 91 | $324.6M |
| Q1 2021 | 87 | $283.0M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Insight Molecular Diagnostics Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Broadwood Capital Inc | 4,929,066 | $14.5M | 1.10% | +2,420,000+96.5% | Added |
| AWM Investment Company, Inc. | 1,097,175 | $3.24M | 0.44% | +342,889+45.5% | Added |
| Pura Vida Investments, LLC | 495,345 | $1.46M | 1.77% | −28,583−5.5% | Reduced |
| Vanguard Group Inc | 244,489 | $721.2K | 0.00% | −3,384−1.4% | Reduced |
| Geode Capital Management, LLC | 92,691 | $273.5K | 0.00% | +30,258+48.5% | Added |
| Morgan Stanley | 78,696 | $232.2K | 0.00% | −44,515−36.1% | Reduced |
| BlackRock Inc. | 72,827 | $214.8K | 0.00% | +12,640+21.0% | Added |
| Defender Capital, LLC. | 55,220 | $162.9K | 0.06% | −665−1.2% | Reduced |
| FNY Investment Advisers, LLC | 23,654 | $69.0K | 0.05% | +23,654 | New |
| State Street Corp | 19,554 | $57.7K | 0.00% | +3,265+20.0% | Added |
| Northern Trust Corp | 17,346 | $51.2K | 0.00% | +17,346 | New |
| Renaissance Technologies LLC | 10,418 | $30.7K | 0.00% | −1,800−14.7% | Reduced |
| Tower Research Capital LLC (TRC) | 3,069 | $9.05K | 0.00% | +1,189+63.2% | Added |
| Advisor Group Holdings, Inc. | 1,127 | $3.32K | 0.00% | +1,030+1,061.9% | Added |
| UBS Group AG | 835 | $2.46K | 0.00% | −29−3.4% | Reduced |
| The PNC Financial Services Group, Inc. | 500 | $1.48K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 416 | $1.23K | 0.00% | +206+98.1% | Added |
| JPMorgan Chase & Co | 154 | $454 | 0.00% | 00.0% | Unchanged |
| Riggs Asset Managment Co. Inc. | 50 | $148 | 0.00% | 00.0% | Unchanged |
| Piscataqua Savings Bank | 25 | $73 | 0.00% | 00.0% | Unchanged |
| Coppell Advisory Solutions LLC | 10 | $30 | 0.00% | +10 | New |
| Albion Financial Group | 7 | $21 | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 1 | $3 | 0.00% | 00.0% | Unchanged |
| NBC Securities, Inc. | 0 | $0 | 0.00% | −150−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −61−100.0% | Sold out |
| Comerica Bank | 0 | $0 | 0.00% | −23−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −13−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −80−100.0% | Sold out |